

31 July 2020

Tender results

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018 and the 2019/20 Invitation to Tender, dated 1 November 2019.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of August 2020 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or the 12th of August 2020 (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Hydrocortisone	Crm 1%; 500 g Jar	\$17.15	\$17.15	Hydrocortisone (PSM) (API Consumer Brands)	1 September 2020	1 December 2020

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Hydrocortisone	Crm 1%; 500 g Jar	\$17.15	\$17.15	Hydrocortisone (PSM) (API Consumer Brands)	1%	1 September 2020	1 December 2020

2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Bupropion hydrochloride	Tab modified-release 150 mg; 30 tablet blister pack	\$11.00	\$11.00	Zyban (GlaxoSmithKline NZ Limited)	1 December 2020	1 March 2021
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs; 168 tablet blister pack	\$4.67	\$4.98	Ginet (Rex Medical Ltd)	1 January 2021	1 April 2021
Losartan potassium	Tab 12.5 mg; 84 tablet blister pack	\$1.39	\$1.56	Losartan Actavis (Teva Pharma Australia Pty Ltd)	1 October 2020	1 January 2021
Losartan potassium	Tab 25 mg; 84 tablet blister pack	\$1.63	\$1.84	Losartan Actavis (Teva Pharma Australia Pty Ltd)	1 October 2020	1 January 2021
Losartan potassium	Tab 50 mg; 84 tablet blister pack	\$2.00	\$2.25	Losartan Actavis (Teva Pharma Australia Pty Ltd)	1 October 2020	1 January 2021
Losartan potassium	Tab 100 mg; 84 tablet blister pack	\$2.31	\$3.50	Losartan Actavis (Teva Pharma Australia Pty Ltd)	1 October 2020	1 January 2021
Naltrexone hydrochloride	Tab 50 mg; 30 tablet blister pack	\$112.55	\$133.33	Naltraccord (Teva Pharma Australia Pty Ltd)	1 October 2020	1 January 2021

4. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Goserelin	Implant 3.6 mg, syringe; 1 prefilled syringe pack	\$66.48	\$65.68	Goserelin -Teva (Teva Pharma Australia Pty Ltd)	1 December 2020	1 May 2021	Zoladex (AstraZeneca)
Goserelin	Implant 10.8 mg, syringe; 1 prefilled syringe pack	\$177.50	\$122.37	Goserelin -Teva (Teva Pharma Australia Pty Ltd)	1 December 2020	1 May 2021	Zoladex (AstraZeneca)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Bupropion hydrochloride	Tab modified-release 150 mg; 30 tablet blister pack	\$11.00	\$11.00	Zyban (GlaxoSmithKline NZ Limited)	1%	1 December 2020	1 March 2021
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs; 168 tablet blister pack	\$4.67	\$4.98	Ginet (Rex Medical Ltd)	1%	1 January 2021	1 April 2021
Losartan potassium	Tab 12.5 mg; 84 tablet blister pack	\$1.39	\$1.56	Losartan Actavis (Teva Pharma Australia Pty Ltd)	1%	1 October 2020	1 January 2021
Losartan potassium	Tab 25 mg; 84 tablet blister pack	\$1.63	\$1.84	Losartan Actavis (Teva Pharma Australia Pty Ltd)	1%	1 October 2020	1 January 2021
Losartan potassium	Tab 50 mg; 84 tablet blister pack	\$2.00	\$2.25	Losartan Actavis (Teva Pharma Australia Pty Ltd)	1%	1 October 2020	1 January 2021
Losartan potassium	Tab 100 mg; 84 tablet blister pack	\$2.31	\$3.50	Losartan Actavis (Teva Pharma Australia Pty Ltd)	1%	1 October 2020	1 January 2021
Naltrexone hydrochloride	Tab 50 mg; 30 tablet blister pack	\$112.55	\$133.33	Naltraccord (Teva Pharma Australia Pty Ltd)	1%	1 October 2020	1 January 2021

6. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Goserelin	Implant 3.6 mg, syringe; 1 prefilled syringe pack	\$66.48	\$65.68	Goserelin -Teva (Teva)	1%	1 December 2020	1 May 2021	Zoladex (AstraZeneca)
Goserelin	Implant 10.8 mg, syringe; 1 prefilled syringe pack	\$177.50	\$122.37	Goserelin -Teva (Teva)	1%	1 December 2020	1 May 2021	Zoladex (AstraZeneca)
Metronidazole	Inj 5 mg per ml, 100 ml bag; 10 bag pack	\$55.00	\$27.50	Baxter (Baxter Healthcare Ltd)	1%	1 September 2020	1 February 2021	AFT (bottle) (AFT); Colpocin-T (bottle) (Multichem)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

- the 2018/19 Invitation to Tender, dated 1 November 2018, and
- the 2019/20 Invitation to Tender, dated 1 November 2019.

2018/19 Invitation to Tender

Chemical name	Line item
Adapalene	Crn 0.1%
Adapalene	Gel 0.1%
Amoxicillin clavulanate	Inj 500 mg with clavulanic acid 100 mg
Amoxicillin clavulanate	Inj 1000 mg with clavulanic acid 200 mg
Beclomethasone dipropionate	Metered aqueous nasal spray, 50 mcg per dose
Beclomethasone dipropionate	Metered aqueous nasal spray, 100 mcg per dose
Bupivacaine hydrochloride with glucose	Inj 0.5% with glucose, 4 ml ampoule
Fentanyl	Inj 20 mcg per ml, 100 ml bag
Fentanyl	Inj 10 mcg per ml, 50 ml prefilled syringe
Fentanyl	Inj 10 mcg per ml, 10 ml syringe
Ganciclovir	Inj 500 mg
Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride	Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet

Chemical name	Line item
Minocycline hydrochloride	Cap 100 mg
Pemetrexed	Powder for infusion, 500 mg
Sodium citrate	Oral liq 8.8% (300 mmol/l)

2019/20 Invitation to Tender

Chemical name	Line item
Carvedilol	Tab 6.25 mg
Carvedilol	Tab 12.5 mg
Carvedilol	Tab 25 mg
Diclofenac sodium	Inj 25 mg per ml, 3 ml
Ibuprofen	Tab 200 mg
Glyceryl trinitrate	Spray 400 mcg per dose
Lacosamide (current access)	Inj 10 mg per ml, 20 ml
Lacosamide (current access)	Tab 50 mg
Lacosamide (current access)	Tab 100 mg
Lacosamide (current access)	Tab 150 mg
Lacosamide (current access)	Tab 200 mg
Lacosamide (widened access)	Tab 50 mg

Chemical name	Line item
Lacosamide (widened access)	Tab 100 mg
Lacosamide (widened access)	Tab 150 mg
Lacosamide (widened access)	Tab 200 mg
Oestradiol	Tab 1 mg
Oestradiol	Tab 2 mg
Oestradiol	TDOS 25 mcg per day
Oestradiol	TDOS 50 mcg per day
Oestradiol	TDOS 75 mcg per day
Oestradiol	TDOS 100 mcg per day
Oestradiol with norethisterone	Tab 1 mg with 0.5 mg norethisterone acetate
Oestradiol with norethisterone	Tab 2 mg with 1 mg norethisterone acetate
Oestradiol with norethisterone	Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg (oestradiol tab (12) and 1 mg oestradiol tab (6)

For products included in the 2018/19 or 2019/20 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.